Abstract: Azathioprine (AZA) is widely used in the treatment of autoimmune inflammatory diseases. AZA is normally rapidly and almost completely converted to 6-mercaptopurine (6-MP) in the liver, which is further metabolized into a variety of pharmacologic active thiopurine metabolites. 6-MP is catabolized by xanthine oxidase (XO) to the inactive metabolite 6-thiouric acid. The authors report the case of a woman with chronic autoimmune pancreatitis unable to form active thiopurine metabolites. The 55-year-old woman presented with weight loss, progressive elevation of liver transaminases, and serum amylase. She was treated with prednisolone 30 mg/day (1 mg/kg) and AZA was increased to 75 mg/day (2.5 mg/kg); this was later increased to 150 mg/day (5 mg/kg). Despite good patient compliance, the active metabolites of AZA, 6-thioguanine nucleotides (6-TGN), and 6-methylmercaptopurine ribonucleotides (6-MMPR) could not be detected in the erythrocytes (RBC). Subsequently, AZA was switched to high-dose 6-MP (2.5 mg/kg) and the XO inhibitor allopurinol was added. After 1 week, this combination led to a high 6-TGN level of 616 pmol/8 3 10 8 RBC and a 6-MMPR level of 1319 pmol/8 3 10 8 RBC. Three weeks after starting treatment, 6-TGN and 6-MMPR even reached toxic levels (1163 pmol/8 3 10 8 RBC and 10015 pmol/8 3 10 8 RBC, respectively) so that 6-MP treatment was discontinued. To elucidate this finding, 6-MP (1.7 mg/kg) was prescribed for 3 days without allopurinol. The woman was not able to form active thiopurine metabolites. According to the authors, this is the first report of a patient unable to form detectable active thiopurine metabolites on AZA and 6-MP therapy despite good patient compliance. High XO activity led to an inability to form detectable levels of active thiopurine metabolites 6-TGN and 6-MMPR. This finding emphasizes the important role of XO in the biotransformation of thiopurines.
INTRODUCTION
Azathioprine (AZA) is clinically used in regimens of organ transplantations and for immunosuppression in the treatment of chronic autoimmune inflammatory diseases.
AZA is a thiopurine prodrug and has no immunosuppressive activity. The pharmacologic action is based on the formation of 6-mercaptopurine (6-MP) in the liver, which is metabolized into the pharmacologic active 6-thioguaninenucleotides (6-TGN) and 6-methylmercaptopurine ribonucleotides (6-MMPR). 1 We describe a woman who was unable to form active thiopurine metabolites.
CASE REPORT
A 55-year-old woman (weight, 30 kg; height, 1.57 m) with chronic autoimmune pancreatitis was unsuccessfully treated with AZA 50 mg/day (1.7 mg/kg) for 6 months. She presented with weight loss (3 kg), progressive elevation of liver transaminases, and serum amylase. The woman was treated with 30 mg prednisolone per day (1 mg/kg), which was tapered by 5 mg each week, and the AZA dosage was increased to 75 mg/day (2.5 mg/kg). In this period, she was admitted several times for short stays in the hospital. After 5 weeks, no active thiopurine metabolites (6-TGN and 6-MMPR) were detected in erythrocytes despite good patient compliance, also verified during the hospital stay. For this reason, the AZA dose was increased to 150 mg daily (5 mg/kg). Almost 3 weeks later, once again, none of the active metabolites of AZA were detected. 6-TGN and 6-MMPR levels in erythrocytes were measured using a highperformance liquid chromatography assay previously reported by Derijks and colleagues. 2 Subsequently, AZA was switched to highdose 6-MP [75 mg/day (2.5 mg/kg)] and 100 mg/day allopurinol was added. After 1 week treatment with 6-MP and allopurinol, the 6-TGN and 6-MMPR levels were 616 pmol/8 3 10
8 red blood cells (RBC) and 1319 pmol/8 3 10 8 RBC, respectively. Three weeks after starting treatment, the 6-TGN level was 1163 pmol/8 3 10
8 RBC and the 6-MMPR level 10015 pmol/8 3 10 8 RBC. These levels of 6-TGN and 6-MMPR were above the upper limits of the therapeutic ranges (values 500 and 5700, respectively). 2, 3 The woman developed leukopenia (,4.0 3 10 9 leukocytes/L) so that treatment with 6-MP and allopurinol was discontinued. A week later, the 6-TGN and 6-MMPR levels decreased to 686 pmol/8 3 10 8 RBC and 4027 pmol/8 3 10 8 RBC, respectively (Fig. 1 ).
To clarify this finding, 3 months later, the woman agreed to take 6-MP for 3 days without allopurinol: day 1, 25 mg/day (0.8 mg/kg); and on days 2 and 3, 50 mg/day (1.7 mg/kg). On day 4, 6-TGN and 6-MMPR could not be detected in erythrocytes.
Genotyping of the enzyme thiopurine S-methyltransferase (TPMT) revealed a wild-type TPMT H/H (*1/*1) genotype; the woman is an extensive metabolizer of thiopurines.
DISCUSSION
To our knowledge, this is the first report of a patient who was not able to form detectable active thiopurine metabolites, even on treatment with a high-dose AZA of 5 mg/kg per day.
As mentioned before, the pharmacologic action of AZA is based on the formation of 6-MP in the liver, which is affected by elimination of the imidazole moiety. This conversion is catalyzed by the enzyme glutathione S-transferase (GST). 4 Ecklund et al studied the catalytic activities of the numerous human GSTs in the biotransformation of AZA. This study showed that three different GSTs, A1-1, A2-2, and M1-1, expressed at high levels in the liver and small intestine are the main enzymes that mediate the release of 6-MP from AZA by the nucleophilic substitution involving glutathione. The uncatalyzed reaction of azathioprine with glutathione was estimated to be less than 1% of GST-catalyzed biotransformation. Because important interindividual differences in the expression of human GSTs have been discovered, the authors concluded that in view of the predominance of GST-catalyzed bioactivation of AZA over the nonenzymatic reaction with glutathione, individual differences in GST expression will affect the release of 6-MP and the formation of its metabolites. The polymorphism of GST M1-1 could be especially highly influential to the metabolism of AZA. 4 A polymorphism of one of these GST subtypes could result in low (or no) formation of 6-MP from AZA.
The fact that the woman did not form detectable 6-TGN and 6-MMPR metabolites on exclusively 6-MP indicates that polymorphisms in the gene encoding GST cannot explain our finding.
The transformation of 6-MP into the various metabolites occurs along three competing metabolic routes: two catabolic by TPMT or xanthine-oxidase (XO) and one anabolic by hypoxanthine phosphoribosyl transferase (HPRT) (Fig. 2) .
The enzyme TPMT methylates 6-MP to 6-MMP. Furthermore, TPMT enables methylation of other compounds in the metabolic pathway, which may result in additional potentially active or hepatotoxic 6-MMPR metabolites. TPMT activity exhibits high interindividual variation as a result of genetic polymorphism. The frequency distribution of TPMT activity in the white population is trimodal; one in 300 subjects have undetectable activity, 11% have intermediate activity, and approximately 89% of the population have high enzyme activity. An inverse relationship was demonstrated between erythrocyte TPMT activity and 6-TGN levels. TPMT determines the balance between 6-MMPR and 6-TGN. The higher the activity of TPMT, the less 6-MP is available for transformation to active 6-TGN.
1 FIGURE 1. Thiopurine use and 6-TGN/6-MMPR levels in time. 6-TGN, 6-thioguaninenucleotides; 6-MMPR, 6-methylmercaptopurine ribonucleotides.
FIGURE 2. Proposed thiopurine metabolism. AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-MMP, 6-methylmercaptopurine; 6-TUA, 6-thiouric acid; 6-TIMP, 6-thioinosine monophosphate; 6-TXMP, 6-thioxanthosine monophosphate; 6-TIDP, 6-thioinosine diphosphate; 6-TITP, 6-thioinosine triphosphate; 6-MMPR, 6-methylmercaptopurine ribonucleotides; 6-TGN, 6-thioguaninenucleotides; 6-MTGN, 6-methylthioguaninenucleotides; GST, glutathione S-transferase; XO, xanthine oxidase; TPMT, thiopurine S-methyltransferase; HPRT, hypoxanthine phosphoribosyl transferase; IMPD, inosine monophosphate dehydrogenase; GMPS, guanosine monophosphate synthetase; MPK, monophosphate kinase; ITPA, inosine triphosphate pyrophosphatase. In our case, TPMT genotyping revealed a wild-type TPMT H/H (*1/*1) genotype, which means that the woman is an extensive metabolizer of thiopurines. TPMT is not the cause of our finding, because variation in TPMT activity results in another ratio between 6-TGN and 6-MMPR levels and not in undetectable levels of both metabolites.
HPRT carries out the first anabolic step to produce 6-thioinosine monophosphate, which subsequently is transformed into a variety of thiopurine nucleotide metabolites. 1 There is only limited information on the range of HPRT activities in the healthy population. HPRT is completely deficient in people with the very rare Lesch-Nyhan syndrome with characteristic symptoms like hyperuricemia, spasticity, self-mutilation, and developmental retardation. Because HPRT catalyzes the conversion of 6-MP into 6-thioinosine monophosphate, there will not be an immunosuppressive effect of AZA or 6-MP in HPRT-deficient patients. 6 HPRT is partially deficient in people with the Kelley-Seegmiller syndrome and can also give rise to a wide range of neurologic symptoms and renal insufficiency. 7 The characteristic symptoms of a (partial) HPRT deficiency were missing in our case. Moreover, because 6-MP in combination with allopurinol led to high 6-TGN and 6-MMPR levels in erythrocytes demonstrates the woman is not HPRT-deficient.
XO is involved in the oxidation of endogenous purines and pyrimidines as well as thiopurines. In humans, the highest activities of XO are found in the intestine and the liver; most other tissues show low activity. 8 Differences in the activity of XO have implications with regard to individual variation in the biotransformation of 6-MP, contributing to a large patient variation in the bioavailability of 6-MP after an oral dose. Individual differences in XO enzyme activity could be determined either by genetic or other factors such as dietary habits and inflammatory diseases. [8] [9] [10] [11] [12] Competitive inhibition of XO with allopurinol (300 mg/day) pretreatment results in a fivefold increase of the bioavailability of oral 6-MP. 13 Raised erythrocyte 6-TGN levels have been demonstrated in patients receiving allopurinol.
14 Furthermore, dangerous myelotoxicity resulting from concurrent use of allopurinol and 6-MP/AZA has been reported. 15, 16 For concurrent use of allopurinol and 6-MP or AZA, it is recommended to reduce 6-MP/AZA dosage to a one-third or less of normal. 13 Generally, approximately two-thirds of a normal dose seems to be inactivated by the catabolic pathway of XO. Interestingly, Sparrow et al investigated the effect of 100 mg/day allopurinol in thiopurine nonresponders with normal TPMT activity and preferential shunting to 6-MMP. A reduction to 25% to 50% of the original 6-MP/AZA dose in combination with allopurinol led to an effective shift toward 6-TGN. 17 In our case, erythrocyte 6-TGN and 6-MMPR levels were not detectable after high-dose AZA (5 mg/kg per day). However, an equivalent dose of 6-MP (2.5 mg/kg per day) in combination with the XO-inhibitor allopurinol resulted in a myelotoxic 6-TGN level in the first week after the start of treatment. Apparently, the addition of allopurinol inhibited the extensive conversion of 6-MP to 6-thiouric acid catalyzed by XO, resulting in 6-MP available for the formation of 6-TGN and 6-MMPR. Patient noncompliance during treatment of AZA and 6-MP in combination with allopurinol was ruled out during hospitalization. Therefore, in our patient, a relatively high XO enzyme activity seems to be the only plausible explanation for our finding. To elucidate our finding, we applied 6-MP without allopurinol for 3 days. 6-TGN and 6-MMPR are normally detected already after 3 days, as shown in the pharmacokinetic analysis of 6-MP by Derijks and collegues. 2 The fact that we could not detect 6-TGN and 6-MMPR levels on day 4 after 3 days of treatment with 6-MP (average 1.3 mg/kg per day) without allopurinol confirms our hypothesis.
CONCLUSION
To our knowledge, this is the first report of a patient who is not able to form detectable active thiopurine metabolites on the treatment with a therapeutic dose of AZA and 6-MP despite good patient compliance. In daily practice, patients with low or zero levels are mostly considered noncompliant. However, our finding indicates that high XO activity could lead to a disability to form active thiopurine metabolites. In the past decade, much attention has been paid to the role of TPMT in thiopurine metabolism. This case emphasizes the importance of XO in the biotransformation of thiopurines in which high XO activity resulted in nondetectable levels of the active thiopurine metabolites 6-TGN and 6-MMPR.
